|
مقاله
|
Abstract
|
|
|
Title:
|
Short-term results of trabeculectomy using adjunctive intracameral bevacizumab: A randomized controlled trial
|
Author(s):
|
Ghasem Fakhraie, Hadi Ghadimi, Yadollah Eslami, Reza Zarei, Massood Mohammadi, Zakieh Vahedian, Mostafa Mafi, Sasan Moghimi
|
Presentation Type:
|
Oral
|
Subject:
|
Glaucoma
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Zakieh Vahedian
|
Affiliation :(optional)
|
Glaucoma service, Farabi Eye Hospital, Tehran, Iran
|
E mail:
|
vahedian.z@gmail.com
|
Phone:
|
|
Mobile:
|
09121947330
|
|
|
Purpose:
|
To investigate the outcome of trabeculectomy with or without adjunctive intracameral bevacizumab.
|
Methods:
|
In this double-blind, randomized clinical trial 71 patients with primary open-angle or pseudoexfoliation glaucoma were randomly assigned to receive either 1.25 mg intracameral bevacizumab (n=36) or balanced salt solution (n=35) at the end of trabeculectomy. Success was defined as intraocular pressure (IOP) between 6 and 21 mmHg at last postoperative visit with (qualified) or without (complete) glaucoma medications without additional glaucoma surgery.
|
Results:
|
Thirty-two patients in bevacizumab group and 33 in placebo group completed a mean follow-up of 10.7±2.1 and 10.5±2.5 months, respectively (P=0.731). The mean preoperative IOP was 28.25±5.64 mmHg and 29.11±4.65 mmHg in the bevacizumab and placebo groups, respectively (P=0.485). Last visit IOP was 14.5±3.7 mmHg in the bevacizumab group and 18.55±3.64 mmHg in the placebo group (P<0.001). At last visit, complete success was achieved in 26 cases (81.3%) of bevacizumab group and 16 cases (48.5%) of placebo group (P<0.006). Filtering bleb leak during the first postoperative month was seen in 11 (34%) and in 3 (9%) cases of bevacizumab and placebo groups, respectively (P=0.013).
|
Conclusion:
|
A single 1.25 mg dose of intracameral bevacizumab improves the success of trabeculectomy; however, it increases the risk of early bleb leakage.
|
Attachment:
|
|
|